Cambridge UK, 12th December 2012- Bactevo has spun-off from the antibiotics discovery company Discuva to develop its core technology expertise in the Industrial Biotechnology sector. Bactevo is a Cambridge UK-based company utilising its proprietary molecular engineering technologies, known as TarGET, to enable the use of bacteria for the synthesis of chemicals from sustainable resources. With an experienced Biotech management team and exceptional science, the company’s objective is to provide safe, renewable and high-value Industrial Biotechnology alternatives to the creation of products without excessive energy requirements or polluting chemicals.
“The core platform developed and validated at Discuva has been highly successful in the discovery of new antibiotics. It was a logical next step to create a spin-off, Bactevo, focused on exploiting powerful new developments of this new technology in other industries. We look forward to continuing the innovative commercially-minded culture in our sister company to provide biotechnology solutions in multiple industries,” said David Williams, co-founder and Executive Director of Bactevo.
Contact:
David Williams, PhD
Executive Director
Bactevo Ltd
Tel: +44(0)1223 423506
david.williams@bactevo.com
About TarGET
The TarGET (Targeted Genomic Evolution Technologies), platform exploits the huge continuing advances in Next Generation Sequencing technologies combined with high-throughput functional genomic mutations, analysis and intelligent algorithms to give an unparalleled understanding of the internal process within a microbe necessary to survive and perform optimised specific functions in industrial environments. TarGET quickly produces bacteria perfectly optimised for a specific industrial process, maximising the use of feedstock and energy inputs to complete catalytic tasks efficiently, whilst boosting yields. This technology has the potential to transform the field of Industrial Biotechnology making the reality of ‘clean’ chemicals an achievable goal.